Intercept winds down NASH programme after FDA pulls plug on Ocaliva
The FDA has blocked the approval of Intercept’s NASH therapy, pushing the company to restructure its investment strategy.
The FDA has blocked the approval of Intercept’s NASH therapy, pushing the company to restructure its investment strategy.
What's Your Reaction?
